Solvias’ new center expands its global footprint to six centers of excellence and marks the company’s second site in North America.

The new facility is its flagship North American site for large molecule analytical services designed to accelerate the development and commercialization of innovative biologics, the company said. The site, which is expected to create approximately 200 new jobs over the next three years, is being rolled out in two phases.

The first phase comprises a 20,000-square-foot space for cGMP release testing – featuring cell-based potency and molecular assays – and is operational immediately.

In a second phase, an additional area of 30,000-square-foot is expected to open in July 2025, offering expanded capabilities for stability testing and biophysical characterization.

According to Solvias, the new center offers comprehensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and other biologics, from preclinical stages to commercial release.

“This Center of Excellence in RTP is a milestone in Solvias’ global growth journey,” said Archie Cullen, CEO of Solvias. “Combining our team’s expertise with advanced technology, we aim to set a new benchmark for delivering high-quality, reliable analytical support.”

“With this investment, we are committed to be an integral part of the US biopharma innovation ecosystem,” said Ilya Koltover, chief commercial officer of Solvias.